公开(公告)号：SE409702B

公开(公告)日：1979-09-03

申请号：SE7413303

申请日：1974-10-22

Applicant: ABBOTT LAB

Inventor： JONES P H ,  KYNCL J ,  OURS C W ,  SOMANI P

IPC: A61K31/195 ,  A01N37/44 ,  A61K31/198 ,  A61K31/22 ,  A61P9/08 ,  C07C237/08 ,  C07C103/50

Abstract: Covers the esters of gamma -glutamyl amide of dopamine selected from the group consisting of -CH2-CH2-NHO ¦ PARALLEL C-CH2-CH2-CH-C-OR PARALLEL ¦ ONH2 where R is a C1-C20 alkyl radical, and a pharmaceutically acceptable acid addition salt thereof. Also covers the use of said esters of gamma -glutamyl amide of dopamine to increase renal blood flow by administering said amide to warm-blooded mammals by clinically acceptable routes of administration such as oral, parenteral, rectal, etc.

公开(公告)号：PH12277A

公开(公告)日：1978-12-12

申请号：PH18862

申请日：1976-09-02

Applicant: ABBOTT LAB

Inventor： JONES P ,  OURS C ,  KYNCL J

IPC: A61K31/235 ,  A61P9/08 ,  A61P9/12 ,  C07C237/08 ,  C07C271/22 ,  A61K31/225 ,  C07C103/10 ,  C07C103/28 ,  C07C103/52 ,  C07C103/56 ,  C07C103/365

Abstract: This invention covers diacylated derivatives of gamma -glutamyl dopamine selected from the group consisting of where R is a C1-C12 straight or branched chain alkyl radical, a phenyl ring or a substituted phenyl ring and R' is H or a C1-C7 alkyl, and a pharmaceutically acceptable acid addition salt thereof.

公开(公告)号：DK552074A

公开(公告)日：1975-07-07

申请号：DK552074

申请日：1974-10-22

Applicant: ABBOTT LAB

Inventor： JONES P H ,  KYNCL J ,  OURS C W ,  SOMANI P

IPC: A61K31/195 ,  A01N37/44 ,  A61K31/198 ,  A61K31/22 ,  A61P9/08 ,  C07C237/08 ,  C07C103/50

Abstract: Covers the esters of gamma -glutamyl amide of dopamine selected from the group consisting of -CH2-CH2-NHO ¦ PARALLEL C-CH2-CH2-CH-C-OR PARALLEL ¦ ONH2 where R is a C1-C20 alkyl radical, and a pharmaceutically acceptable acid addition salt thereof. Also covers the use of said esters of gamma -glutamyl amide of dopamine to increase renal blood flow by administering said amide to warm-blooded mammals by clinically acceptable routes of administration such as oral, parenteral, rectal, etc.

公开(公告)号：SE7413303A

公开(公告)日：1975-04-24

申请号：SE7413303

申请日：1974-10-22

Applicant: ABBOTT LAB

Inventor： JONES P H ,  KYNCL J ,  OURS C W ,  SOMANI P

IPC: A61K31/195 ,  A01N37/44 ,  A61K31/198 ,  A61K31/22 ,  A61P9/08 ,  C07C237/08 ,  C07C103/50

CPC classification number: A01N37/44 ,  Y10S514/929

公开(公告)号：SE422685B

公开(公告)日：1982-03-22

申请号：SE7611379

申请日：1976-10-13

Applicant: ABBOTT LAB

Inventor： WINN M ,  KYNCL J ,  DUNNIGAN D A ,  JONES P H

IPC: C07D405/12 ,  A61K31/505 ,  A61P9/12 ,  A61P25/04 ,  C07D309/08 ,  C07D405/14

Abstract: Described are antihypertensive agents selected from the class consisting of 2[4(tetrahydro-2-furoyl)-piperazino]-4-amino-6,7-dimethoxyquinazoline and 2-[4(tetrahydropyran-2-carbonyl)-piperazinyl]-4-amino-6,7-dimethoxyqui nazoline, and pharmaceutically acceptable acid addition salts thereof. The compounds are highly water soluble and can be administered in time release form as well as parenterally, including intravenously.

公开(公告)号：AU502420B2

公开(公告)日：1979-07-26

申请号：AU1759176

申请日：1976-09-09

Applicant: ABBOTT LAB

Inventor： WINN M ,  KYNCL J ,  DUNNIGAN D A ,  JONES P H

IPC: C07D405/14 ,  A61K31/495 ,  A61K31/505 ,  A61K31/55 ,  A61P9/12 ,  C07D239/84 ,  C07D239/95 ,  C07D243/00 ,  C07D243/08 ,  C07D307/14 ,  C07D405/06 ,  C07D407/14

Abstract: Described are the compounds 2[4(tetrahydro-2-furoyl)-hexahydro-1,4-diazepinyl-1]-4-amino-6,7-dimet hoxy quinazoline and pharmaceutically acceptable acid addition salts thereof. The compounds are useful as antihypertensive agents.

公开(公告)号：SE7609886L

公开(公告)日：1977-03-12

申请号：SE7609886

申请日：1976-09-07

Applicant: ABBOTT LAB

Inventor： JONES P H ,  OURS C W ,  KYNCL J

IPC: A61K31/235 ,  A61K31/225 ,  A61P9/08 ,  A61P9/12 ,  C07C237/08 ,  C07C271/22 ,  C07C103/50

Abstract: This invention covers diacylated derivatives of gamma -glutamyl dopamine selected from the group consisting of where R is a C1-C12 straight or branched chain alkyl radical, a phenyl ring or a substituted phenyl ring and R' is H or a C1-C7 alkyl, and a pharmaceutically acceptable acid addition salt thereof.

公开(公告)号：SE8008533L

公开(公告)日：1980-12-04

申请号：SE8008533

申请日：1980-12-04

Applicant: ABBOTT LAB

Inventor： WINN M ,  KYNCL J ,  DUNNINGAN D A ,  JONES P H

IPC: C07D405/12 ,  A61K31/505 ,  A61P9/12 ,  A61P25/04 ,  C07D309/08 ,  C07D405/14

Abstract: Described are antihypertensive agents selected from the class consisting of 2[4(tetrahydro-2-furoyl)-piperazino]-4-amino-6,7-dimethoxyquinazoline and 2-[4(tetrahydropyran-2-carbonyl)-piperazinyl]-4-amino-6,7-dimethoxyqui nazoline, and pharmaceutically acceptable acid addition salts thereof. The compounds are highly water soluble and can be administered in time release form as well as parenterally, including intravenously.

公开(公告)号：AU500839B2

公开(公告)日：1979-05-31

申请号：AU1718776

申请日：1976-08-26

Applicant: ABBOTT LAB

Inventor： JONES P H ,  OURS C W ,  KYNCL J

IPC: A61K31/225 ,  A61K31/235 ,  A61P9/08 ,  A61P9/12 ,  C07C237/08 ,  C07C271/22 ,  C07C103/50 ,  A61K31/215 ,  C07C125/06

Abstract: This invention covers diacylated derivatives of gamma -glutamyl dopamine selected from the group consisting of where R is a C1-C12 straight or branched chain alkyl radical, a phenyl ring or a substituted phenyl ring and R' is H or a C1-C7 alkyl, and a pharmaceutically acceptable acid addition salt thereof.

公开(公告)号：AU498925B2

公开(公告)日：1979-03-29

申请号：AU1655776

申请日：1976-08-04

Applicant: ABBOTT LAB

Inventor： WINN M ,  KYNCL J ,  DUNNIGAN D A ,  JONES P H

IPC: C07D405/12 ,  A61K31/505 ,  A61P9/12 ,  A61P25/04 ,  C07D309/08 ,  C07D405/14 ,  A61K31/495 ,  C07D5/06

Abstract: Described are antihypertensive agents selected from the class consisting of 2[4(tetrahydro-2-furoyl)-piperazino]-4-amino-6,7-dimethoxyquinazoline and 2-[4(tetrahydropyran-2-carbonyl)-piperazinyl]-4-amino-6,7-dimethoxyqui nazoline, and pharmaceutically acceptable acid addition salts thereof. The compounds are highly water soluble and can be administered in time release form as well as parenterally, including intravenously.